☆ 4.8 Article

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine

FRONTIERS IN IMMUNOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Huanle Luo et al.

Summary: Increasing evidence suggests immune responses are associated with COVID-19 outcomes. IgG subclasses and cytokines had significant correlations with disease severity. Older patients and those with comorbidities showed higher antibody levels and affected IgG1 and IgG3 responses.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Infectious Diseases

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Julien Favresse et al.

Summary: The CRO-VAX HCP study investigated the early antibody response in healthcare professionals who received two doses of the BNT162b2 mRNA COVID-19 vaccine. Results showed that in previously infected individuals, a single dose of the vaccine may be sufficient, as they had higher antibody titres compared to uninfected individuals.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Catherine J. Reynolds et al.

Summary: Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.

SCIENCE (2021)

Add to Collection

News Item Multidisciplinary Sciences

COVID VACCINE BOOSTERS: THE MOST IMPORTANT QUESTIONS

Ewen Callaway

Summary: Some countries are considering deploying extra vaccine doses in response to concerns over waning immunity and SARS-CoV-2 variants, but it is still unclear to scientists whether most people need them.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Microbiology

Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera

Ranawaka A. P. M. Perera et al.

Summary: The surrogate virus neutralization test (sVNT) showed high sensitivity and specificity compared to the plaque reduction neutralization test (PRNT90) in human, canine, cat, and hamster sera. There was no cross-reactivity to other coronaviruses in both SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Biochemical Research Methods

Computational Analysis of Multiparametric Flow Cytometric Data to Dissect B Cell Subsets in Vaccine Studies

Simone Lucchesi et al.

CYTOMETRY PART A (2020)

Add to Collection

Review Immunology

From Bivariate to Multivariate Analysis of Cytometric Data: Overview of Computational Methods and Their Application in Vaccination Studies

Simone Lucchesi et al.

VACCINES (2020)

Add to Collection

Article Medicine, Research & Experimental

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Kento T. Abe et al.

JCI INSIGHT (2020)

Add to Collection

Review Immunology

Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population

Annalisa Ciabattini et al.

SEMINARS IN IMMUNOPATHOLOGY (2020)

Add to Collection

Review Immunology

Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations

Ignacio Sanz et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Review Immunology

Vaccination in the elderly: The challenge of immune changes with aging

Annalisa Ciabattini et al.

SEMINARS IN IMMUNOLOGY (2018)

Add to Collection

Article Biochemical Research Methods

FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data

Sofie Van Gassen et al.

CYTOMETRY PART A (2015)

Add to Collection

Article Biochemical Research Methods

flowDensity: reproducing manual gating of flow cytometry data by automated density-based cell population identification

Mehrnoush Malek et al.

BIOINFORMATICS (2015)

Add to Collection

Review Immunology

Origin and function of circulating plasmablasts during acute viral infections

Katja Fink

FRONTIERS IN IMMUNOLOGY (2012)

Add to Collection

Article Immunology

Systems biology of vaccination for seasonal influenza in humans

Helder I. Nakaya et al.

NATURE IMMUNOLOGY (2011)

Add to Collection

Article Biochemical Research Methods

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking

Matthew D. Wilkerson et al.

BIOINFORMATICS (2010)

Add to Collection

Article Biochemical Research Methods

flowCore: a Bioconductor package for high throughput flow cytometry

Florian Hahne et al.

BMC BIOINFORMATICS (2009)

Add to Collection

Article Biochemical Research Methods

A new Logicle display method avoids deceptive effects of logarithmic scaling for low signals and compensated data

David R. Parks et al.

CYTOMETRY PART A (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.